Oberland Capital Management LLC announced the closing of the Oberland Capital Healthcare Solutions Fund and affiliated funds, with $1.05 billion of capital commitments at the Fund's hard cap.  The Solutions Fund will provide capital to biopharmaceutical, diagnostic and medical device companies advancing products in late-stage clinical development or under review by regulatory authorities in exchange for royalties on the products once approved and commercialized. 

"We are very grateful for the support we received from both existing and new investors for this differentiated strategy," said Andrew Rubinstein, Managing Partner of Oberland Capital.  "Their confidence in our investment team and approach, including our exclusive focus on products that treat serious diseases, is both humbling and motivating." 
Oberland Capital secured commitments from a diversified and global set of institutional investors, including public and private pension plans, endowments and foundations, sovereign wealth funds and family offices.  The Solutions Fund, which is Oberland Capital's third fund, was oversubscribed.

"We look forward to providing healthcare companies with an attractive, non-dilutive solution to their capital needs and to helping them bring their important new therapeutics, diagnostics and medical devices to market as soon as possible," said Jean-Pierre Naegeli, Managing Partner of Oberland Capital.

Ropes & Gray LLP acted as legal counsel for the Fund.